At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed advanced, unresectable and/or metastatic or relapsed/refractory solid tumor
- ✓At least one measurable lesion per RECIST 1.1
- ✓Exhausted or refused established treatment options, or not eligible for them
- ✓Lesion amenable to pre-treatment and on-treatment biopsy with patient consent
- ✕Any investigational or antitumor treatment within 4 weeks or 5 half-lives (whichever shorter)
- ✕Prior STING agonist therapy
- ✕Prior intolerability of anti-PD-1 or anti-PD-L1 therapy
- ✕History of allergy or hypersensitivity to study agent components
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours
In Brief
A Phase 1 clinical trial evaluating BI 1703880 and Ezabenlimab for Solid Tumors. Currently recruiting, targeting 66 participants across 13 sites in 4 countries.
Detailed Summary
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab. BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1703880 is given to people for the first time. Participants get BI 1703880 and ezabenlimab as infusions into a vein. During the first 6 weeks, they get BI 1703880 once a week. Later, they get BI 1703880 every 3 weeks. After the first 3 weeks, they get ezabenlimab in addition every 3 weeks. Participants can get BI 1703880 for up to 1 year and ezabenlimab for up to 2 years as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. At these visits, the doctors check participants' health and take note of any unwanted effects.
Study Details
Timeline
Interventions
BI 1703880
Ezabenlimab